ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CCCC vs EDIT // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

C4 Therapeutics Inc. (NASDAQ) VS. Editas Medicine Inc. (NASDAQ) • 15-METRIC TALLY: CCCC 2 — EDIT 1
■ METRIC PARITY
options-implied-move
—
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CCCC VS. EDIT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CCCC EDIT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -24.46% — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 1.00% 25.40% -24.40 EDIT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.6 50.1 +6.50 CCCC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $414.6M $410.1M $4.5M CCCC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CCCC REV EDIT REV CCCC GROSS % EDIT GROSS % CCCC FCF EDIT FCF
FY 2025 $35.9M $40.5M — — -$99.3M -$165.8M
FY 2024 $35.6M $32.3M — — -$65.3M -$219.1M
FY 2023 $20.8M $78.1M — — -$106.8M -$132.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CCCC // BETA —
EDIT // BETA —